ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Home - Ipro sur NovoSeven® Préparation injectable stable à la température ambiante
Information professionnelle sur NovoSeven® Préparation injectable stable à la température ambiante:Novo Nordisk Pharma AG
Information professionnelle complèteDDDAfficher les changementsimprimé 
Composit.Forme gal.Indic./emploiPosolog./mode d'empl.Contre-Ind.PrécautionsInteract.Grossesse
Apt.conduiteEffets indésir.SurdosagePropriétésPharm.cinét.Donn.précl.RemarquesNum. Swissmedic
PrésentationsTitulaireMise à jour 
B02BD08 - Coagulation Factor ViiaATC-DDD Version 2016. Source: WHO
B - Blood and Blood Forming Organs
 
B02 - Antihemorrhagics
 
B02B - Vitamin K and Other Hemostatics
 

The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.).

B02BD - Blood Coagulation Factors

This group comprises all blood coagulation factors, thrombin etc., incl. preparations for local use, and their combinations. Gene therapy products replacing coagulation factors are also classified in this group.
For systemic formulations of fibrinogen (factor I), see - B02BB - Fibrinogen.
Prothrombin complexes containg three or all four factors are classified in B02BD01 coagulation factor IX, II, VII and X.
Both human derived and recombinant factor VIII and factor IX products will be classified in B02BD02 - coagulation factor VIII and B02BD04 - coagulation factor IX, respectively.

No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).

B02BD08 - Coagulation Factor Viia
 
Classification ATC | Médicaments de A à Z | Nouveaux enregistrements
2024 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home